Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting

PURPOSE: The therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and their combinations with endocrine therapies. In this scenario, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawood, Shaheenah, Konstantionva, Maria, Dent, Rebecca, Perazzo, Florencia, Kim, Sung-Bae, Villarreal-Garza, Cynthia, Franco, Sandra, Dai, Ming-Shen, Simon, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351081/
https://www.ncbi.nlm.nih.gov/pubmed/34372853
http://dx.doi.org/10.1186/s12919-021-00224-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351081/
https://www.ncbi.nlm.nih.gov/pubmed/34372853
http://dx.doi.org/10.1186/s12919-021-00224-5

Ejemplares similares